| Authors: |
Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, INSERM U900 Research Unit, Paris-Saclay University, Paris, France., André F; Institut Gustave Roussy, Paris, France., Helland Å; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Mileshkin L; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Minnaard W; Missie Tumor Onbekend, Amsterdam, Netherlands., Schiel A; Norwegian Medicines Agency, Oslo, Norway., Taskén K; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Thomas DM; Garvan Institute of Medical Research, Darlinghurst, Australia., Veronese ML; Incyte International Biosciences Sàrl, Morges, Switzerland., Durán-Pacheco G; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Leyens L; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Rufibach K; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Thomas M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: a.kraemer@Dkfz-Heidelberg.de. |
